Evaluation of Peripheral Blood Smear for Myelodysplasia in Breast Cancer Patients who Received Adjuvant Antracycline | Zendy

Hasan Mutlu | Zendy; Zeki Akça | Zendy; Havva Üsküdar Teke | Zendy; Hediye Uğur | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evaluation of Peripheral Blood Smear for Myelodysplasia in Breast Cancer Patients who Received Adjuvant Antracycline

Author(s) -

Hasan Mutlu,

Zeki Akça,

Havva Üsküdar Teke,

Hediye Uğur

Publication year - 2011

Publication title -

eurasian journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.337

H-Index - 13

eISSN - 1308-8742

pISSN - 1308-8734

DOI - 10.5152/eajm.2011.36

Subject(s) - medicine , anthracycline , gastroenterology , breast cancer , myelodysplastic syndromes , myeloid , leukopenia , peripheral blood , cancer , chemotherapy , bone marrow

Therapy-related myeloid neoplasms (t-MN) account for approximately 10% to 20% of all cases of AML (acute myeloid leukemia), MDS (myelodysplastic syndrome) and MDS/MPN (myelodysplastic syndrome/myeloproliferative neoplasms), MDS, and MDS/MPN. In our study, we evaluated peripheral blood smear samples and hemogram values in breast cancer patients who were receiving adjuvant anthracycline regimens and were in remission.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research